Expression And Significance Of PRL-3 In Prostatic Cancer Tissues

Prostatic carcinoma is the most common malignancy diagnosed and the second leading cause of cancer-related death for men living in the United States. Patients with early diagnosis is mainly based on serum PSA levels, Gleason score, and clinical stage of disease at the time of diagnosis. According to these criteria for diagnosis, treatment measures are generally divided into two classes were active monitoring or active treatment vigilance, for monitoring patients suffering active alert and possible delay treatmen, But active treatment for prostate cancer is including vesssed, radiation therapy, hormone therapy, cryotherapy, Whatever the method to improve disease to improve the quality of life of patients, and there were no significant differences in mortality. Prostate cancer gene therapy at the relevant research is more and more attention. Prostate cancer insidious be hidden that for early diagnosis and prevention of very difficult, the best to the best treatment plan hasn't been clear standard, to improve the quality of life of patients and controls illness is not taken into account and gene therapy is a new breakthrough in prostate cancer treatment. PRL-3 was the newly discovered a inhibits PTP enzymes in the process of conciliation proteins in cells and heal play an important role in physiology and in tumor cells reduce endogenous PRL - 3 can reduce the cell motility and transfer characteristics. We have every reason to phase 3 - PRL target gene therapy is likely to become prostate cancer gene therapy of new breakthrough. The broad field of gene therapy promises a number of innovative treatments that are likely to become important in preventing deaths from prostatic carcinoma.Methods: Through the collection of prostate cancer resection specimen line immunohistochemical study, Which cancerous tissue for 48 cases and 12 cases of cancer tissue hyperplasia. According to the classification of tumor pathological grading and combined with Gleason scores prostate tumors pathology classification system will be divided into: Well-differentiated cancers 11cases; M-differentiated cancers 17cases; L-differentiated cancers 20 cases. Through the RT - PCR and constructing PRL - 3 eukaryotic expression vector for prostate cancer development process and 3 - PRL compared gene relationship.Results:1. Immunohistochemical: 48 cases prostate tissue expression rate is positive 79.20% (38/48), And cancer tissue hyperplasia expression rate is only 25.00% (12), (3 /12)prostate tissue in PRL - 3 expression rate significantly higher hyperplasia, 48 patients who prostate tissue PRL - 3 expression on statistical analysis.The Results: PRL - 3 with age, family history, the expression of pathological types and histological grade not related( P > 0.05), And the clinical stages Gleason scores related closely related( P < 0.05).Conclusion: PRL - 3 expression and prostate cancer closely related.,which is the clinical and pathological and related prostate cancer. Gene transfer technology for cancer treatment holds great promise for increasing the effectiveness of current chemotherapeutic treatment regimens.The field of cancer gene therapy is rapidly maturing and will no doubt be part of the future of prostate cancer therapeutics.